Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hexyl aminolevulinate - Photocure

Next Previous
X
Search
Drug Profile

Hexyl aminolevulinate - Photocure

Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; APL-1702; APL-1706; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhotoCure
  • Developer Asieris Pharmaceuticals; Genotests; Ipsen; Juno Pharmaceuticals; Photocure
  • Class Amino acids; Antineoplastics; Esters; Imaging agents; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Preregistration Cervical intraepithelial neoplasia
  • Discontinued Colorectal cancer

Most Recent Events

  • 31 May 2024 National Medical Products Administration (NMPA) accepts NDA for Hexyl aminolevulinate for cervical intraepithelial neoplasia for review in China
  • 31 May 2024 Preregistration for Cervical intraepithelial neoplasia in China (Topical) before May 2024
  • 16 May 2024 Asieris Pharmaceuticals anticipates for the market approvals of Hexyl aminolevulinate (Cevira®) for Cervical intraepithelial neoplasia in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top